House Calls and Peer Mentorship (HC+PM)
Comparing the Effectiveness of House Calls and Peer Mentorship to Reduce Racial Disparities in Live Donor Kidney Transplantation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Black race (including possible Cape Verdean, Haitian, Dominican)
- ≥18 yrs old
- English speaking
- Meets eligibility criteria for kidney transplant evaluation
- Ability to provide informed consent
- Resides within 1.5 hr drive of HC educator
Exclusion Criteria:
- Temporarily Unavailable (TU) on the waiting list and TU is likely to exceed 6 months based on judgement of kidney transplant team
- Awaiting combined kidney-liver transplantation
- Awaiting simultaneous pancreas-kidney transplantation
- Participation in another study to increase the likelihood of LDKT
- Prior participation in a transplant HC
- Prior or current participation in the NKF PM program
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Usual Care
All enrolled patients will receive Usual Care for transplant candidates at our two centers, which includes individual meetings with transplant providers, attendance at a patient group education session in the transplant center (focused on the specifics of the transplant experience), and a transplant education binder.
|
|
|
Active Comparator: Usual Care (UC) + House Calls (HC)
Patients and their invited guests will be scheduled for one House Call.
A house call is meeting done at a patient's home with transplant health educators facilitating a discussion on topics related to living kidney donation.
Patients and guests also receive an information packet containing several brochures providing information about the living donation process, common concerns and misperceptions, and donation resources and information about our transplant center (e.g., copy of our quarterly newsletter, contact information).
Patients in the group will also receive Usual Care, the regular education on living donation, provided as part of their routine transplant care.
|
60 to 90 minute home based educational intervention which will be administered by a health educator.
|
|
Experimental: UC + HC + Peer Mentorship
Patients in this condition will receive the Usual Care and the House Calls intervention as described previously.
In addition, participants will receive access to a Peer Mentor trained by the National Kidney Foundation following their House Call.
|
60 to 90 minute home based educational intervention which will be administered by a health educator.
A National Kidney Foundation Peer Mentor will be assigned to the participant to provide contact and support to study participants.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Live donor kidney transplants
Time Frame: 1 Year Post-Intervention
|
The primary outcome for this study is the proportion of enrolled patients with live donor kidney transplants after 1 year.
|
1 Year Post-Intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Live donor evaluations
Time Frame: 1 Year Post-Intervention
|
A secondary outcome for the study is the proportion of enrolled patients with a live donor evaluation at the one-year endpoint.
A live donor evaluation is defined as the completion of a transplant evaluation to determine whether a potential living donor is eligible to donate.
|
1 Year Post-Intervention
|
|
Live donor inquiries
Time Frame: 1 Year Post-Intervention
|
A secondary outcome for the study is proportion of enrolled patients with live donor inquiries at the one-year endpoint.
A live donor inquiry is when an individual contacts the transplant center to express interest in living donation, regardless of when they complete the entire live donor evaluation.
|
1 Year Post-Intervention
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improvement in live donor kidney transplant knowledge measured through Living Donation Kidney Transplant Knowledge (LDKT-K) scale score
Time Frame: Baseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-Intervention
|
An improvement in patient knowledge is measured by the change in score of a scored instrument, the Living Donation Kidney Transplant Knowledge Scale (LDKT-K).
The LDKT-K is a scored true or false questionnaire that tests patient's knowledge on living donation.
A higher score indicates that a participant answered more questions correctly.
|
Baseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-Intervention
|
|
Improvement in live donor kidney transplant readiness measured through Living Donation Kidney Transplant Readiness scale (LDKT-R) score
Time Frame: Baseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-Intervention
|
Improvement in patient readiness to pursue LDKT is measured by a scored instrument, the Living Donation Kidney Transplant Readiness Scale (LDKT-R).
The LDKT-R is a 5-point scale where patient's self report their readiness to pursue living donation and where in the process they are (i.e., they are beginning to think about living donation, have spoken with potential donors, etc.) A higher score on this assessment indicates greater readiness to pursue LDKT.
|
Baseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-Intervention
|
|
Reduced health care mistrust measured through Health Care Distrust Scale (HCDS) score
Time Frame: Baseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-Intervention
|
Reduction in patient mistrust towards the health care system is measured through a scale, the Health Care Distrust Scale (HCDS).
This scale is a 5-point Likert scale that measures the degree of agreement patients have on statements regarding their trust of the medical system.
For example, one such statement reads "the health care systems lie to make money."
A higher score on this assessment indicates higher levels of mistrust of the health care system.
|
Baseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-Intervention
|
|
Reduced live donor kidney transplant concerns measured through measured Living Donation Kidney Transplant Concerns scale (LDKT-C) score
Time Frame: Baseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-Intervention
|
Patient's concerns towards LDKT is measured using a 5-point scale, the Living Donation Kidney Transplant Concerns scale (LDKT-C) where patients indicate their level of concern towards common concerns patients have regarding living donation.
A higher score on this assessment indicates higher levels of concern towards living donation.
|
Baseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-Intervention
|
|
Greater amount of time spent discussing LDKT and higher quality interactions measured through the Talking About Living Donation (TaLKeD) instrument
Time Frame: Baseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-Intervention
|
The time patients speak with others about LDKT and whether these interactions are of higher quality compared to pre-intervention is measured through a self-report instrument, Talking About Living Donation (TaLKeD), that asks the cumulative time patient's spoke with others (family, friends, etc.) about living donation and their perceived quality of these interactions (poor, fair, good, very good, excellent).
|
Baseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-Intervention
|
|
Improvement in self-efficacy discussing LDKT measured through Living Donation Kidney Transplant Self-Efficacy scale (LDKT-SE) score
Time Frame: Baseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-Intervention
|
Patient's self-efficacy towards doing activities to pursue LDKT (e.g.
willingness and confidence to approach others for donation, following-up with potential donors) is measured through a self-report instrument, the Living Donation Kidney Transplant Self-Efficacy (LDKT-SE) scale.
A higher score on this assessment indicates higher self-efficacy for patients pursuing LDKT.
|
Baseline, 1 Week Post-Intervention, 6 Weeks Post-Intervention, and 12 Weeks Post-Intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: James R Rodrigue, Ph.D., Beth Israel Deaconess Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2017P000521
- PCORI 1609-36589 (Other Grant/Funding Number: Patient-Centered Outcomes Research Institute (PCORI))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.